Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SRL-172
- Development stage
- Unknown
- Lead developer
- Silence Therapeutics
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
SRL-172 is an inactivated whole cell vaccine derived from the non-tuberculous mycobacterium *Mycobacterium vaccae*. It was developed as an immunotherapeutic agent and BCG booster for tuberculosis (TB) prevention and as adjunctive therapy in cancer. The preparation consists of heat-killed *M. vaccae* cells administered intradermally. Its mechanism of action is believed to involve modulation of the immune response, enhancing cell-mediated immunity against *Mycobacterium tuberculosis* and potentially other antigens[2][7][9]. Clinical trials have evaluated its use as an adjunct to standard anti-TB chemotherapy in HIV-positive adults with pulmonary TB, where it was found to be safe but did not significantly improve survival or bacteriological outcomes[1][4]. In oncology, studies have explored its combination with chemotherapy for non-small-cell lung cancer (NSCLC) and mesothelioma; while overall survival was not improved, some quality-of-life benefits were observed[3][5][8]. The manufacturing process for a related product (DAR-901) has since been developed from the SRL-172 master cell bank.
- Brand names
- SRL-172SRL172SRL 172
- Other names
- Mycobacterium vaccae (heat-killed)killed Mycobacterium vaccaeinactivated Mycobacterium vaccaeM. vaccae vaccine
02
Targets
TLR2 (Toll-like Receptor 2)
Beyond the preview
Go deeper on SRL-172.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SRL-172.